Sodium‐glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?-Reference-Cited by-同舟云学术

Sodium‐glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?

Published:2022-03-02 Issue:3 Volume:63 Page:199-206
ISSN:2192-8312
Container-title:JIMD Reports
language:en
Short-container-title:JIMD Reports

Author:

Kaczor Magdalena¹^ORCID,Greczan Milena¹^ORCID,Kierus Karolina²,Ehmke vel Emczyńska‐Seliga Ewa¹^ORCID,Ciara Elżbieta³^ORCID,Piątosa Barbara⁴^ORCID,Rokicki Dariusz¹^ORCID,Książyk Janusz¹^ORCID,Wesół‐Kucharska Dorota¹^ORCID

Affiliation:

1. Department of Paediatrics, Nutrition and Metabolic Diseases Children's Memorial Health Institute Warsaw Poland

2. Department of Paediatrics, Rheumatology, Immunology and Metabolic Bone Diseases Medical University of Bialystok Białystok Poland

3. Department of Medical Genetics Children's Memorial Health Institute Warsaw Poland

4. Histocompatibility Laboratory Children's Memorial Health Institute Warsaw Poland

Publisher

Wiley

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmd2.12278

Reference8 articles.

1. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

2. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency

3. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor

4. Neutropenia in glycogen storage disease Ib

5. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib;Current Pediatrics;2024-07-12

2. Case report: The success of empagliflozin therapy for glycogen storage disease type 1b;Frontiers in Endocrinology;2024-06-11

3. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review;Pediatric Drugs;2024-04-18

4. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop;Molecular Genetics and Metabolism;2024-03

5. Glycogen storage disease type Ib: modern understanding of the pathogenesis of neutropenia and prospects for its treatment with empagliflozin;Pediatric pharmacology;2023-11-17